Charles River Laboratories International (CRL) vs Medpace (MEDP)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Charles River Laboratories International (CRL) has outperformed Medpace (MEDP) over the past year, gaining 75.3% versus a gain of 13.5%. Over five years, MEDP leads with a +222.2% price change compared with -25.2% for CRL. Medpace is the larger company by market cap ($17.08 billion vs $14.54 billion), about 1.2 times the size.
On valuation, Charles River Laboratories International trades at a lower forward P/E (23.6x vs 31.7x for Medpace). Medpace converts more of its revenue into profit, with a net margin of 17.8% versus -3.6%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CRL | MEDP |
|---|---|---|
| Share price | $301.79 | $612.05 |
| Market cap | $14.54B | $17.08B |
| 1-day change | +1.27% | +1.55% |
| YTD return | +51.29% | +7.31% |
| 1-year return | +75.32% | +13.50% |
| 5-year return | -25.21% | +222.16% |
| P/E ratio (TTM) | — | 35.36 |
| Forward P/E | 23.62 | 31.69 |
| EPS (TTM) | $-4.86 | $17.31 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $4.02B | $2.53B |
| Revenue growth (YoY) | -0.85% | +19.97% |
| Net income (latest FY) | $-144.34M | $451.12M |
| Operating margin | 0.63% | 21.14% |
| Net margin | -3.59% | 17.83% |
| 52-week high | $333.30 | $677.90 |
| 52-week low | $146.20 | $373.00 |
| Distance from 52-week high | -9.45% | -9.71% |
| Analyst consensus | buy | hold |
| Avg. price target upside | +1.06% | -3.30% |
| Average volume | 957.45K | 273.89K |
| Shares outstanding | 48.17M | 27.91M |
| Employees | 18,300 | 6,500 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Commercial Physical & Biological Resarch | Biotechnology: Commercial Physical & Biological Resarch |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CRL has outperformed MEDP by 61.8 percentage points over the past year.
- Medpace is more profitable, keeping 17.8 cents of every revenue dollar as net income versus -3.6 cents for Charles River Laboratories International.
- Medpace grew revenue faster in its latest fiscal year (+19.97% vs -0.85%).
About Charles River Laboratories International
CRL stock →Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally.
Health Care · Biotechnology: Commercial Physical & Biological Resarch · 18,300 employees
About Medpace
MEDP stock →Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, Asia, South America, Africa, and Australia.
Health Care · Biotechnology: Commercial Physical & Biological Resarch · 6,500 employees
CRL vs MEDP FAQ
Which is bigger, Charles River Laboratories International or Medpace?
Medpace (MEDP) is larger, with a market capitalization of $17.08B compared with $14.54B for Charles River Laboratories International (CRL).
Which stock has performed better over the past year, CRL or MEDP?
CRL returned +75.32% over the past 12 months, compared with +13.50% for MEDP (price return, excluding dividends). Past performance does not predict future results.
Are Charles River Laboratories International and Medpace in the same industry?
Yes. Both are classified in the Biotechnology: Commercial Physical & Biological Resarch industry within the Health Care sector.